Bridgefront Capital, LLC Kodiak Sciences Inc. Transaction History

Bridgefront Capital, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$5.04 - $9.48 $67,142 - $126,292	-13,322 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$7.09 - $89.45 $94,452 - $1.19 Million	13,322 New	13,322 $103,000
Q1 2021 May 17, 2021	SELL	$110.45 - $164.47 $316,660 - $471,535	-2,867 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$60.78 - $154.03 $174,256 - $441,604	2,867 New	2,867 $421,000

104

39.8M

7.6K

3.5K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $138M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Bridgefront Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgefront Capital, LLC with notifications on news.